PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
Items 301–400 of 1,000
PPARs and LXRs: atherosclerosis goes nuclear
Barish, G. D., & Evans, R. M. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.03.003 · Cited by 77
Plutzky, J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00614-3 · Cited by 82
Potential Health-modulating Effects of Isoflavones and Metabolites via Activation of PPAR and AhR
Medjakovic, S., Mueller, M., & Jungbauer, A. (2010) · Nutrients · doi:10.3390/nu2030241 · Cited by 88
Peroxisome proliferator-activated receptors and the metabolic syndrome
Bragt, M. C. E., & Popeijus, H. E. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.053 · Cited by 79
Yokoyama, S. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.1 · Cited by 86
Marcil, V., DELVIN, E. E., Sané, A. T., Tremblay, A., & Levy, E. H. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.08.024 · Cited by 79
“Additionally, growing evidence suggests that peroxisome proliferatoractivated receptors (PPARs) exert antiatherogenic effects by enhancing cholesterol efflux via activation of the liver X receptor (LXR)–ABCA1 pathway [22,23].”
BackgroundFenofibrate: Metabolic and Pleiotropic Effects
Tsimihodimos, V., Miltiadous, G., Daskalopoulou, S., Mikhailidis, D., & Elisaf, M. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773942 · Cited by 74
Qiu, F.-F., Xie, L., Ma, J., Luo, W., Zhang, L., Chao, Z., Chen, S., Nie, Q., Lin, Z., & Zhang, X. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00449 · Cited by 78
“The DEGs ABCA1, CPT1A, LPL, and SLC27A1, which were down-regulated in WC.D120.”
BackgroundInfluentialRole of PPARγ in macrophage biology and atherosclerosis
Zhang, L., & Chawla, A. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.10.006 · Cited by 82
Genetics of HDL regulation in humans
Miller, M. J., Rhyne, J., Hamlette, S., Birnbaum, J., & Rodriguez, A. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200306000-00007 · Cited by 77
The vascular biology of atherosclerosis
Plutzky, J. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.010 · Cited by 96
Argmann, C. A., Sawyez, C. G., McNeil, C. J., Hegele, R. A., & Huff, M. W. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000058860.62870.6e · Cited by 74
Ulven, S. M., Dalen, K. T., Gustafsson, J.-Å., & Nebb, H. I. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400119-jlr200 · Cited by 71
Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home
Fitzgerald, M. L., Moore, K. J., & Freeman, M. W. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0318-y · Cited by 81
Quantitative Trait Loci and Candidate Genes Regulating HDL Cholesterol: A Murine Chromosome Map
Wang, X., & Paigen, B. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000030201.29121.a3 · Cited by 75
Metabolic effects of thia fatty acids
Berge, R. K., Skorve, J., Tronstad, K. J., Berge, K., Gudbrandsen, O. A., & Grav, H. J. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200206000-00010 · Cited by 78
Nuclear Receptors and Inflammatory Diseases
Wang, K., & Wan, Y.-J. Y. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-231 · Cited by 72
Anti‐atherogenic effect of berberine on LXRα‐ABCA1‐dependent cholesterol efflux in macrophages
Lee, T., Pan, C., Peng, C., Kou, Y. R., Chen, C., Ching, L., Tsai, T., Chen, S., Lyu, P., & Shyue, S. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22667 · Cited by 72
“To further investigate the role of ABCA1 in the lipid-lowering effect of berberine, THP-1-derived macrophages were pretreated with an ABCA1 inhibitor, DIDS [Chinetti et al., 2001], or ABCA1 neutralizing antibody in the presence of berberine.”
MethodNuclear receptors as drug targets in metabolic diseases: new approaches to therapy
Tobin, J. F., & Freedman, L. P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.07.004 · Cited by 77
Staels, B. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x36440 · Cited by 72
Self-citationMetabolic switching of human myotubes is improved by n-3 fatty acids
Hessvik, N. P., Bakke, S. S., Fredriksson, K., Boekschoten, M. V., Fj⊘rkenstad, A., Koster, G., Hesselink, M. K., Kersten, S., Kase, E. T., Rustan, A. C., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003319 · Cited by 71
Apetz, N., Münch, G. W., Govindaraghavan, S., & Gyengési, E. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917110635 · Cited by 79
ABC Transporters, Cholesterol Efflux, and Implications for Cardiovascular Diseases
Wang, N., & Westerterp, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_6 · Cited by 75
Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling
Atrih, A., Mudaliar, M., Zakikhani, P., Lamont, D. J., Huang, J. T.-J., Bray, S. E., Barton, G. J., Fleming, S., & Nabi, G. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.24 · Cited by 71
Levi, Z., Shaish, A., Yacov, N., Levkovitz, H., Trestman, S., Gerber, Y., Cohen, H. W., Dvir, A., Rhachmani, R., Ravid, M., et al. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00240.x · Cited by 78
Knight, B. L., Patel, D. D., Humphreys, S. M., Wiggins, D., & Gibbons, G. F. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300042-jlr200 · Cited by 71
“sponse to WY 14,643 and other fatty acid-derived PPAR ligands in human macrophages (13) and liver cells (42) in vitro, we could detect no change in LXR mRNA expression in response to dietary WY 14,643 in the intestine.”
BackgroundPPARs in Inflammation, Atherosclerosis and Thrombosis
Duez, H., Fruchart, J., & Staels, B. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800402 · Cited by 77
Self-citationFourcade, S., Savary, S., Albet, S., Gauthé, D., Gondcaille, C., Pineau, T., Bellenger, J., Bentejac, M., Holzinger, A., Berger, J., et al. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02249.x · Cited by 70
Ahluwalia, P. K., Pandey, R. K., Sehajpal, P. K., & Prajapati, V. K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00107 · Cited by 75
Ligand‐dependent contribution of RXRβ to cholesterol homeostasis in Sertoli cells
Mascrez, B., Ghyselinck, N. B., 渡辺, 光., Annicotte, J., Chambon, P., Auwerx, J. H., & Mark, M. P. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400094 · Cited by 81
Fang, X., Hu, S., Watanabe, T., Weintraub, N. L., Snyder, G. D., Yao, J., Liu, Y., Shyy, J. Y.-J., Hammock, B. D., & Spector, A. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085605 · Cited by 75
“Activation of PPAR decreases cholesterol esterification in macrophages and increases the removal of cholesterol from human macrophage foam cells (Chinetti et al., 2001, 2003; Ricote et al., 2004).”
BackgroundKlopotek, A., Hirche, F., & Eder, K. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100810 · Cited by 83
“Macrophages are able to excrete free cholesterol via ABCAI onto apoAl, and this efflux is stimulated by PPARy (43, 44).”
BackgroundWallert, M., Schmölz, L., Koeberle, A., Krauth, V., Glei, M., Galli, F., Werz, O., Birringer, M., & Stefan Lorkowski, A. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400737 · Cited by 69
Chinetti-Gbaguidi, G., Rigamonti, E., Helin, L., Mutka, A. L., Lepore, M., Fruchart, J. C., Clavey, V., Ikonen, E., Lestavel, S., & Staels, B. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500326-jlr200 · Cited by 69
Self-citationIdentification of a Naturally Occurring Rexinoid, Honokiol, That Activates the Retinoid X Receptor
Kotani, H., Tanabe, H., Mizukami, H., Makishima, M., & Inoue, M. (2010) · Journal of Natural Products · doi:10.1021/np100120c · Cited by 77
Langmann, T., Porsch-Özcürümez, M., Heimerl, S., Probst, M., Moehle, C., Taher, M., Borsukova, H., Kielar, D., Kaminski, W. E., Dittrich-Wengenroth, E., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110270200 · Cited by 69
ABCA1, from pathology to membrane function
Zarubica, A., Trompier, D., & Chimini, G. (2006) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0108-z · Cited by 82
Regulation of ABCG1 expression in human keratinocytes and murine epidermis
Jiang, Y. J., Lu, B., Tarling, E. J., Kim, P., Man, M.-Q., Crumrine, D., Edwards, P. A., Elias, P. M., & Feingold, K. R. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006445 · Cited by 68
Oda, M., Koyanagi, S., Tsurudome, Y., Kanemitsu, T., Matsunaga, N., & Ohdo, S. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.089805 · Cited by 71
“…including fatty acid transport protein, ATP-binding cassette–transporter family A1, and equilibrative nucleoside transporter 1 (Martin et al., 1997; Chinetti et al., 2001; Montero et al., 2012), suggesting that the function and expression of PPARa-targeted transporters may also exhibit circadian…”
BackgroundLipid homeostasis in macrophages – Implications for atherosclerosis
Schmitz, G., & Grandl, M. (2008) · Springer eBooks · doi:10.1007/112_2008_802 · Cited by 77
“expression of ABCA1 and apoE in macrophages (Chinetti et al. 2001) through the activa-”
BackgroundMechanisms of Disease: HDL metabolism as a target for novel therapies
Rader, D. J. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0768 · Cited by 67
Uribarri, J., Cai, W., Pyzik, R., Goodman, S., Chen, X., Zhu, L., Ramdas, M., Striker, G. E., & Vlassara, H. (2014) · Amino Acids · doi:10.1007/s00726-013-1502-4 · Cited by 67
“PPARc is shown to interact with SIRT1 and inhibit its activity via a negative feedback loop that plays a role in cell senescence (Chinetti et al. 2001).”
BackgroundHeterogeneity of high density lipoprotein generated by ABCA1 and ABCA7
Hayashi, M., Abe-Dohmae, S., Okazaki, M., Ueda, K., & Yokoyama, S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500092-jlr200 · Cited by 67
Progress in cardiovascular biology: PPAR for the course
Lazar, M. A. (2001) · Nature Medicine · doi:10.1038/83301 · Cited by 70
Zhang, Y., & Mangelsdorf, D. J. (2002) · Molecular Interventions · doi:10.1124/mi.2.2.78 · Cited by 79
van Oostrom, A. J. H. H. M., van Wijk, J. P. H., & Cabezas, M. C. (2004) · Drugs · doi:10.2165/00003495-200464002-00004 · Cited by 77
Polydatin for treating atherosclerotic diseases: A functional and mechanistic overview
Wu, M., Li, X., Wang, S., Yang, S., Zhao, R., Xing, Y., & Liu, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110308 · Cited by 67
Therapeutic approaches to drug targets in hyperlipidemia
Mahamuni, S. P., Khose, R. D., Menaa, F., & Badole, S. L. (2012) · Biomedicine · doi:10.1016/j.biomed.2012.08.002 · Cited by 72
Mitochondrial specific therapeutic targets following brain injury
Yonutas, H. M., Vekaria, H. J., & Sullivan, P. G. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.007 · Cited by 76
Thomas, J. S., Bramlett, K. S., Montrose, C., FOXWORTHY, P. S., Eacho, P. I., McCann, D., Cao, G., Kiefer, A. D., McCowan, J., Yu, K., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209629200 · Cited by 71
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism
Llaverias, G., Vázquez-Carrera, M., Sánchez, R. M., Noé, V., Ciudad, C. J., Laguna, J. C., & Alegret, M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400049-jlr200 · Cited by 66
van Stijn, C. M. W., Kim, J., Barish, G. D., Tietge, U. J. F., & Tangirala, R. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086404 · Cited by 65
Pharmacological effects of polydatin in the treatment of metabolic diseases: A review
Luo, J., Chen, S., Wang, L., Zhao, X., & Piao, C. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154161 · Cited by 69
Farnier, M. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3390 · Cited by 63
“All these effects contribute to the increase of plasma HDL-C concentrations (Guerin et al 1996; Chinetti et al 2001; Mardones et al 2003; Fruchart and Duriez 2006).”
BackgroundNing, Y., Bai, Q., Lu, H., Li, X., Pandak, W. M., Zhao, F., Chen, S., Ren, S., & Yin, L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.006 · Cited by 64
“[6] Chinetti G, Lestavel S, Bocher V, et al.”
BackgroundPan, H., Yang, Q., Huang, G., Ding, C., Cao, P., Huang, L., Xiao, T., Guo, J., & Su, Z. (2016) · Food & Nutrition Research · doi:10.3402/fnr.v60.31137 · Cited by 69
Sterol regulation of scavenger receptor class B type I in macrophages
Yu, L., Cao, G., Repa, J. J., & Stangl, H. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300461-jlr200 · Cited by 76
Wang, M., & Tafuri, S. R. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10492 · Cited by 69
Taskinen, M.-R., Sullivan, D. R., Ehnholm, C., Whiting, M., Zannino, D., Simes, R. J., Keech, A. C., & Barter, P. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.178228 · Cited by 63
Hsu, S., & Huang, C. (2006) · Journal of Nutrition · doi:10.1093/jn/136.7.1779 · Cited by 69
Colin, S., Briand, O., Touche, V., Wouters, K., Baron, M., Pattou, F., Hanf, R., Tailleux, A., Chinetti, G., Staels, B., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs227 · Cited by 63
Self-citationPalmer, A. M., Murphy, N., & Graham, A. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.12.001 · Cited by 69
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
“The expression of ABCA-1 and ABCG-1 is induced by PPAR and PPAR either directly [150], or indirectly via the liver-X-receptor (LXR), the expression of which is enhanced by PPARs [151].”
BackgroundWallert, M., Mosig, A. S., Rennert, K., Funke, H., Ristow, M., Pellegrino, R. M., Cruciani, G., Galli, F., Lorkowski, S., & Birringer, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.009 · Cited by 63
Prediction of PPAR- ligand-mediated physiological changes using gene expression profiles
Frederiksen, K. S., Wulff, E. M., Sauerberg, P., Mogensen, J. P., Jeppesen, L., & Fleckner, J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300239-jlr200 · Cited by 70
Assembly of high density lipoprotein by the ABCA1/apolipoprotein pathway
Yokoyama, S. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000169346.15450.90 · Cited by 63
Telmisartan Enhances Cholesterol Efflux from THP-1 Macrophages by Activating PPARγ
Nakaya, K., Ayaori, M., Hisada, T., Sawada, S., Tanaka, N., Iwamoto, N., Ogura, M., Yakushiji, E., Kusuhara, M., Nakamura, H., et al. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.133 · Cited by 61
Yu, S., Cao, W.-Q., Kashireddy, P., Meyer, K., Jia, Y., Hughes, D. E., Tan, Y., Feng, J., Yeldandi, A. V., Rao, M. S., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106480200 · Cited by 61
Taketa, K., Matsumura, T., Yano, M., Ishii, N., Senokuchi, T., Motoshima, H., Murata, Y., Kim-Mitsuyama, S., Kawada, T., Itabe, H., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m703318200 · Cited by 60
Brunham, L. R., Kruit, J. K., Hayden, M. R., & Verchere, C. B. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0090-x · Cited by 67
McCarthy, C., Lieggi, N. T., Barry, D., Mooney, D., de Gaetano, M., James, W. G., McClelland, S., Barry, M. C., Escoubet‐Lozach, L., Li, A. C., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302587 · Cited by 67
Xu, Y., Wang, Q., Cook, T. J., & Knipp, G. T. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20973 · Cited by 65
Vascular effects of TZDs: New implications
Blaschke, F., Spanheimer, R. G., Khan, M. A., & Law, R. E. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.009 · Cited by 58
“In addition, previous in vitro studies demonstrated that PPAR-γ agonists induce cholesterol efflux from human macrophages and macrophage-derived foam cells through stimulation of the ABCA1 pathway (Chinetti et al., 2001).”
BackgroundPeroxisome proliferator-activated receptors in macrophage biology: friend or foe?
Moore, K. J., Fitzgerald, M. L., & Freeman, M. W. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00007 · Cited by 60
Liu, Y., Sun, Y., Lin, X., Zhang, D., Hu, C., Liu, J., Zhu, Y., Gao, A., Han, H., Chai, M., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.106968 · Cited by 68
Milionis, H., Moutzouri, Kei, & Elisaf (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
Solleti, S. K., Simon, D. M., Srisuma, S., Arikan, M. C., Bhattacharya, S., Rangasamy, T., Bijli, K. M., Rahman, A., Crossno, J. T., Shapiro, S. D., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00287.2014 · Cited by 59
Lipocalin 2 Deficiency Alters Estradiol Production and Estrogen Receptor Signaling in Female Mice
Guo, H., Zhang, Y., Brockman, D. A., Hahn, W. S., Bernlohr, D., & Chen, X. (2012) · Endocrinology · doi:10.1210/en.2011-1642 · Cited by 66
Bujold, K., Rhainds, D., Jossart, C., Febbraio, M., Marleau, S., & Ong, H. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp118 · Cited by 54
Effect of Topical PPARβ/δ and PPARγ Agonists on Plaque Psoriasis
Kuenzli, S., & Saurat, J.-H. (2003) · Dermatology · doi:10.1159/000068897 · Cited by 59
The peroxisome proliferator-activated receptor α (PPARα): role in hepatocarcinogenesis
Gonzalez, F. J. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00098-9 · Cited by 60
Regulation of Peroxisome Proliferator-activated Receptor-γ-mediated Gene Expression
Han, J., Hajjar, D. P., Zhou, X., Gotto, A. M., & NICHOLSON, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200685200 · Cited by 67
Peroxisome proliferator-activated receptors in endothelial cell biology
Plutzky, J. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200110000-00006 · Cited by 60
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 62
Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour
Sihag, J., & Jones, P. J. H. (2017) · Obesity Reviews · doi:10.1111/obr.12630 · Cited by 62
Liver X receptor-α mediates cholesterol efflux in glomerular mesangial cells
Wu, J., Zhang, Y., Wang, N., Davis, L. S., Yang, G., Wang, X., Zhu, Y., Breyer, M. D., & Guan, Y. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00123.2004 · Cited by 62
Atherosclerosis in diabetes and insulin resistance
Reusch, J. E. B., & Draznin, B. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00620.x · Cited by 64
Lee, S. S. T., Chan, W.-Y., Lo, C. K. C., Wan, D. C. C., Tsang, D. S. C., & Cheung, W.-T. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400078-jlr200 · Cited by 57
“lesterol through transporter ABCA1, a member of the ATP-binding cassette-transporter family (43, 44).”
BackgroundZaveri, N. T., & Murphy, B. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00063-8 · Cited by 64
Mansoori, A., Sotoudeh, G., Djalali, M., Eshraghian, M., Keramatipour, M., Nasli‐Esfahani, E., Shidfar, F., Alvandi, E., Toupchian, O., & Koohdani, F. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.007 · Cited by 64
“Therefore, impaired reverse cholesterol transport (RCT) has been implicated.10 In RCT process, excess cholesterol is removed from peripheral cells, and returned to the liver for clearance into the bile and ultimately the feces.11 The membraneassociated ATP-binding cassette A1 (ABCA1) has pivotal role in RCT.11 ABCA1 p…”
Peroxisome proliferator-activated receptors: Bridging metabolic syndrome with molecular nutrition
Guri, A. J., Hontecillas, R., & Bassaganya-Riera, J. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.08.006 · Cited by 66
Iizuka, M., Ayaori, M., Uto‐Kondo, H., Yakushiji, E., Takiguchi, S., NAKAYA, K., Hisada, T., Sasaki, M., Komatsu, T., Yogo, M., et al. (2012) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.58.96 · Cited by 61
Temelkova-Kurktschiev, T. S., Hanefeld, M., Chinetti, G., Zawadzki, C., Haulon, S., Kubaszek, A., Koehler, C., Leonhardt, W., Staels, B., & Laakso, M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032120 · Cited by 64
Self-citationRole of Peroxisome Proliferator-Activated Receptor-.GAMMA. in Atherosclerosis - An Update -
Wang, N., Yin, R., Liu, Y., Mao, G., & Fang, X. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0060 · Cited by 64
Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL
Fan, A., Wu, X., Wu, H., Li, L., Huang, R., Zhu, Y., Qiu, Y., Fu, J., Ren, J., & Zhu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085337 · Cited by 61
Gocke, A. R., Hussain, R. Z., Yang, Y., Peng, H., Weiner, J., Ben, L.-H., Drew, P. D., Stüve, O., Lovett‐Racke, A. E., & Racke, M. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713927 · Cited by 54
Chen, J., Wang, C., Wang, C.-P., Sheu, J.-Y., Lin, C.-L., & Lin, H. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.03.026 · Cited by 65
PPARα and PPARγ activators suppress the monocyte-macrophage apoB-48 receptor
Haraguchi, G., Kobayashi, Y., Brown, M. L., Tanaka, A., Isobe, M., Gianturco, S. H., & Bradley, W. A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300077-jlr200 · Cited by 55
The Yin and Yang of carbon nanomaterials in atherosclerosis
Rezaee, M., Behnam, B., Banach, M., & Sahebkar, A. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.10.010 · Cited by 55
Panzenboeck, U., Kratzer, I., Sovic, A., Wintersperger, A., Bernhart, E. M., Hammer, A., Malle, E., & Sattler, W. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.01.013 · Cited by 59
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.